Please assess the completion status of the following clinical trial:

Trial Title: Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically or cytologically confirmed unresectable local advanced/recurrent or metastasis esophageal squamous cell carcinoma;~2. No previous systemic anti-tumor treatment;~3. Subjects must have at least one measurable tumor lesion per RECIST 1.1;~4. Tissue samples should be provided for biomarkers (such as PD-L1) analysis;~5. ECOG: 0-1;~6. Adequate organ and bone marrow function;~Exclusion Criteria:~1. Allergic to monoclonal antibodies, any SHR-1210 components, paclitaxel, cisplatin and other platinum drugs;~2. Prior therapy as follow:~   1. Anti-PD-1 or anti-PD-L1;~  2. Any experimental drugs within 4 weeks of the first dose of study medication;~  3. Received major operations or serious injuries within 4 weeks of the first dose of study medication;~  4. Received last dose of anticancer therapy (including chemotherapy, radiotherapy, targeted therapy, etc.) within 4 weeks of the first dose of study medication;~3. Not recovered to ≤CTCAE 1 from adverse events (except for hair loss) due to a previously anti-tumor treatment;~4. Subjects with any active autoimmune disease or history of autoimmune disease;~5. Pregnancy or breast feeding;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- SHR-1210 + paclitaxel + cisplatin (Type: EXPERIMENTAL): Paclitaxel 175mg/m2, Day 1，cisplatin 75mg/m2，Day 1，SHR-1210 200mg，Day 2，every 3 weeks, maximum 6 cycles, then SHR-1210 maintenance
- placebo+paclitaxel + cisplatin (Type: ACTIVE_COMPARATOR): Paclitaxel 175mg/m2, Day 1，cisplatin 75mg/m2，Day 1，placebo，Day 2，every 3 weeks, maximum 6 cycles, then placebo maintenance

Based on this trial design, predict the completion outcome and termination type (if applicable).